Related Experiment Video
Updated: Jun 20, 2026
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface
Pompiliu Piso1, Gabriel Glockzin, Phillipp von Breitenbuch
1University Medical Center Regensburg, Regensburg, Germany. pompiliu.piso@klinik.uni-regensburg.de
Abstract:
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with high morbidity. The Quality of Life (QoL) assessment in this patient group with a limited life expectancy and high recurrence rate is important. Published data show an impairment of postoperative Quality of Life at 3 months postoperatively with an improvement over 6-12 months at levels higher than the baseline. Standardized instruments QoL have to be included in clinical trials assessing the efficacy of CRS and HIPEC.